Shari Strier
Corneal and Contact Management · Glen Burnie, MDNPI 1881699627
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $581, 4.1 times the $141 reported in 2019.
Across 83 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$273
- Tarsus Pharmaceuticals, Inc.$271
- Sun Pharmaceutical Industries Inc.$190
- Oyster Point Pharma, Inc.$171
- Dompe US, Inc.$154
- Alcon$122
- plus $651 from 14 others
What the payments were for
- Food & beverage$1,77797%
- Education$181%
- Gifts$171%
- Entertainment$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 17 | $273 |
| Tarsus Pharmaceuticals, Inc. | 9 | $271 |
| Sun Pharmaceutical Industries Inc. | 9 | $190 |
| Oyster Point Pharma, Inc. | 9 | $171 |
| Dompe US, Inc. | 6 | $154 |
| Alcon | 6 | $122 |
| Sight Sciences, Inc. | 3 | $111 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $87 |
| Harrow Eye, LLC | 3 | $73 |
| Kala Pharmaceuticals, Inc. | 3 | $70 |
| Bausch & Lomb Americas Inc. | 3 | $63 |
| LKC Technologies, Inc. | 1 | $45 |
| Coopervision Inc. | 2 | $42 |
| Thea Pharma Inc. | 2 | $30 |
| Rxsight Inc | 1 | $25 |
| Glaukos Corporation | 1 | $24 |
| Novartis | 1 | $22 |
| Tearlab Corp | 1 | $21 |
| Optos, Inc. | 1 | $20 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
How this compares
Too few corneal and contact management providers in Marylandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 32 | $27,094 |
| RestasisCyclosporine | 16 | $18,826 |
| LumiganBimatoprost | 18 | $11,500 |
| VevyeCyclosporine | 11 | $7,844 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $5,325 |
| VyzultaLatanoprostene Bunod | 12 | $4,294 |
| Travoprost | 17 | $3,771 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $3,422 |
| Latanoprost | 118 | $1,876 |
| Prednisolone Acetate | 24 | $1,330 |
| Brimonidine Tartrate | 18 | $651 |
| Timolol Maleate | 53 | $636 |
| Doxycycline Monohydrate | 26 | $579 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $493 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 47 | $482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $63 | $31,38844 claims |
| AbbVieRestasis, Lumigan | $273 | $30,32634 claims |
| Harrow Eye, LLCVevye | $73 | $7,84411 claims |
| AlconSimbrinza | $122 | $3,42211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few corneal and contact management providers in Marylandon file to place this against a meaningful peer group, so we don't.
Other corneal and contact management in Glen Burnie
- Lamont BunyonTemple Hills$5K
- Bruce HyattBaltimore$2K
- Sharon MagillAnnapolis$2K
- Gerald FrishmanFrederick$2K
- Chunxia ZhangKensington$1K
- Debra WeltmanRockville$1K
- Vincente SimonciniAnnapolis$970
- Kien LamBaltimore$836
- Steven PinsonBaltimore$750
- Natalia GorskiTowson$513
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.